SequelSEC

NEUROONE MEDICAL TECHNOLOGIES Corp NMTC

Surgical & Medical Instruments & Apparatus · CIK 0001500198 · Fiscal year ends 0930

Revenue
$9.10M
Fiscal year ended 2025-09-30
Operating income
-$4.23M
Fiscal year ended 2025-09-30
Free cash flow
-$2.92M
Fiscal year ended 2025-09-30

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported revenue of $9.10M and net income of -$3.61M for the fiscal year ended 2025-09-30. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from NEUROONE MEDICAL TECHNOLOGIES Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NEUROONE MEDICAL TECHNOLOGIES Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-302022-09-302021-09-302016-12-312015-12-312014-12-31
Revenue$9.10M$3.45M$1.95M$171.17K$178.15K$0$0$773
Cost of revenue$3.96M$2.37M$1.50M$241.96K$275.90KUnavailableUnavailableUnavailable
Gross profit$5.14M$1.08M$456.52K-$70.79K-$97.75KUnavailableUnavailableUnavailable
Operating income-$4.23M-$11.89M-$11.96M-$10.03M-$10.22M-$32.61K-$30.92K-$35.91K
Net income-$3.61M-$12.32M-$11.86M-$10.00M-$9.95M-$47.78K-$62.86K-$36.24K
Research & development$4.98M$5.07M$6.94M$4.93M$3.93MUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 40.15Mshares 26.76Mshares 18.12Mshares 16.00Mshares 10.70MUnavailableUnavailableUnavailable
Pretax income-$3.61M-$12.32M-$11.86M-$10.00MUnavailable-$32.61K-$30.92K-$36.24K
Income tax expenseUnavailableUnavailableUnavailableUnavailable-$271.12K$0$0$0
Diluted EPS$-0.09$-0.46$-0.65$-0.63$-0.93UnavailableUnavailableUnavailable
Selling, general & administrative$7.38M$7.90M$6.93M$6.98M$6.26MUnavailableUnavailableUnavailable
General & administrative$5.85M$6.50MUnavailableUnavailable$6.26M$32.61K$30.92K$36.69K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NEUROONE MEDICAL TECHNOLOGIES Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-302022-09-302021-09-302016-12-312015-12-312014-12-31
Cash & equivalents$6.57M$1.46M$5.32M$8.16M$6.90MUnavailableUnavailableUnavailable
Total assets$10.79M$5.37M$8.10M$12.82M$7.94M$756.93K$1.84K$205
Current assets$10.23M$4.63M$7.31M$12.18M$7.29M$576.04K$1.84K$205
Total liabilities$3.71M$4.55M$1.85M$3.22M$1.38M$1.02M$83.33K$35.59K
Current liabilities$2.30M$2.21M$1.79M$3.10M$1.18M$677.19K$83.33K$35.59K
Total equity incl. NCI$7.07M$822.01K$6.25M$9.60M$6.55M-$266.22K-$81.49K-$35.39K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$2.23M$2.64M$1.73M$704.54K$98.29KUnavailableUnavailableUnavailable
Accounts receivable$1.26M$176.64KUnavailable$33.24K$48.34KUnavailable$0$0
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailable$55.28K$119.56K$202.90KUnavailableUnavailableUnavailable
Accounts payable$1.01M$1.03M$685.10K$927.66K$528.83K$22.36K$10.86K$9.97K

Cash flow

NEUROONE MEDICAL TECHNOLOGIES Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-302022-09-302021-09-302016-12-312015-12-312014-12-31
Operating cash flow-$2.84M-$11.01M-$12.89M-$7.52M-$8.60MUnavailableUnavailableUnavailable
Capital expenditures$81.74K$120.20K$384.12K$275.23K$67.08KUnavailableUnavailableUnavailable
Investing cash flow-$81.74K-$120.20K$2.65M-$3.24M-$67.08KUnavailableUnavailableUnavailable
Financing cash flow$8.03M$7.27M$7.40M$12.02M$11.53MUnavailableUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailable$2.86MUnavailableUnavailableUnavailable
Stock-based compensation$1.26M$1.34M$1.11M$947.21KUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$261.68K$246.79K$199.27K$118.62K$80.75KUnavailableUnavailableUnavailable

Derived

NEUROONE MEDICAL TECHNOLOGIES Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-302022-09-302021-09-302016-12-312015-12-312014-12-31
Free cash flow-$2.92M-$11.13M-$13.27M-$7.79M-$8.67MUnavailableUnavailableUnavailable
Gross margin56.5%31.3%23.4%-41.4%-54.9%UnavailableUnavailableUnavailable
Operating margin-46.5%-344.3%-612.3%-5860.2%-5735.9%UnavailableUnavailable-4646.1%
FCF margin-32.1%-322.4%-679.7%-4553.8%-4866.7%UnavailableUnavailableUnavailable
SBC / revenue13.9%38.9%56.6%553.4%UnavailableUnavailableUnavailableUnavailable
Current ratio4.44x2.09x4.08x3.93x6.17x0.85xUnavailable0.01x
Revenue YoY growth163.5%76.9%1040.7%-3.9%UnavailableUnavailable-100.0%Unavailable
Net margin-39.6%-356.7%-607.4%-5842.0%-5584.3%UnavailableUnavailable-4688.7%
R&D / revenue54.8%146.7%355.5%2879.9%2203.3%UnavailableUnavailableUnavailable
CapEx / revenue0.9%3.5%19.7%160.8%37.7%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NMTC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q/A · Filed 2026-06-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-K · Filed 2025-12-17View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.